Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant what is the number needed to treat, number needed to harm and likelihood to be helped or harmed
International Journal of Clinical Practice,  Evidence Based Medicine  Clinical Article

Citrome L – Vilazodone represents another option for the treatment of major depressive disorder (MDD). Vilazodone appears to have a favourable weight–gain profile based on short–term studies. Sexual side–effects were not consistently demonstrated when assessed using clinical rating scales but spontaneously reported AEs related to sexual functioning were observed. Additional controlled data regarding long–term efficacy and effectiveness will help characterise this new agent when used in maintenance treatment.

Methods
  • The pivotal registration trials were accessed by querying , and for the search term `vilazodone'.
  • Product labeling provided additional information.
  • All available clinical reports of studies were identified.
  • Descriptions of the principal results and calculation of number needed to treat (NNT) and number needed to harm (NNH) for relevant dichotomous outcomes were extracted from the available study reports and other sources of information.

Results
  • Vilazodone is a specific serotonin reuptake inhibitor and serotonin 5HT1A receptor partial agonist.
  • In needs to be administered with food to ensure adequate bioavailability.
  • Approval for the treatment of MDD was based on a clinical development programme that included two 8–week placebo–controlled randomised clinical trials in outpatients with MDD where vilazodone was titrated to a target dose of 40mg/d over the first 2weeks.
  • Both trials evidenced efficacy for vilazodone as measured by the Montgomery Asberg Depression Rating Scale.
  • NNT for response vs. placebo was 8 (95% CI 6–16) and for remission was 14 (95% CI 8–55). NNH vs. placebo for discontinuation because of an adverse event (AE) was 27 (95% CI 15–104).
  • The most commonly encountered AEs (incidence ≥5% and at least twice the rate of placebo) were diarrhoea, nausea, vomiting and insomnia, with NNH values vs. placebo of 6 (95% CI 5–8), 6 (95% CI 5–8), 30 (95% CI 18–82) and 26 (95% CI 16–78), respectively.
  • NNH vs. placebo for any sexual AE was 12 (95% CI 9–18), but systematically collected data using rating scales of sexual function did not reveal treatment associated effects.
  • Vilazodone was not associated with clinically relevant weight change in the short–term trials.
  • In an open–label 1–year study of vilazodone, mean weight increased by 1.7kg among the observed cases.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Pharmacy

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Pharmacy Articles

1 One injection stops diabetes in its tracks Salk Institute News, July 18, 2014

2 FDA approves Afrezza to treat diabetes Full Text FDA Press Announcements, June 30, 2014    Free full text

3 Antibiotic developed 50 years ago may be the key to fighting 'superbugs' University at Buffalo Health and Medicine News, June 19, 2014

4 Levomilnacipran: A new serotonin-norepinephrine reuptake inhibitor for the treatment of major depressive disorder Annals of Pharmacotherapy, July 25, 2014    Review Article    Clinical Article

5 New research indicates statin drugs must be taken properly Michigan State University Health News, July 22, 2014

6 Duke team brings life-saving function to ketchup packets Duke University Health & Medicine News, July 3, 2014

7 European Commission approves Bristol-Myers Squibb’s Daklinza (daclatasvir) across multiple genotypes for the treatment of chronic hepatitis C infection Full Text Bristol Myers-Squibb, August 28, 2014    Free full text

8 “Worm pill” could ease autoimmune disease symptoms Monash University News, August 11, 2014

9 Honey as an effective antimicrobial treatment for chronic wounds Full Text Chronic Wound Care Management and Research, August 21, 2014    Free full text    Review Article

10 FDA approves new type of sleep drug, Belsomra Full Text FDA Press Announcements, August 14, 2014    Free full text

11 Is the standard dose of amoxicillin-clavulanic acid sufficient? Full Text BMC Pharmacology & Toxicology, August 8, 2014    Free full text    Clinical Article

12 Acetaminophen plus ibuprofen versus opioids for treatment of post-tonsillectomy pain in children International Journal of Pediatric Otorhinolaryngology , August 18, 2014    Clinical Article

13 Update on recommendations for use of herpes zoster vaccine Full Text Morbidity and Mortality Weekly Report, August 22, 2014    Free full text

14 Comparison of new-onset gout in adults prescribed chlorthalidone vs hydrochlorothiazide for hypertension The Journal of Clinical Hypertension, September 26, 2014    Clinical Article

15 FDA approves Jardiance to treat type 2 diabetes Full Text FDA Press Announcements, August 4, 2014    Free full text

16 Intracranial hemorrhage risk with the new oral anticoagulants: A systematic review and meta-analysis Journal of Neurology, September 2, 2014    Evidence Based Medicine    Review Article

17 Beta-blockers in heart failure with preserved ejection fraction: A meta-analysis Heart Failure Reviews, July 28, 2014    Evidence Based Medicine    Review Article    Clinical Article

18 FDA approves Striverdi Respimat to treat chronic obstructive pulmonary disease Full Text FDA Press Announcements, August 1, 2014    Free full text

19 Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT Journal of the American Society of Hypertension, September 15, 2014    Clinical Article

20 Digoxin tied to increased risk of death in patients with atrial fibrillation Stanford School of Medicine News, August 12, 2014

Indexed Journals in Pharmacy: Expert Opinion in Pharmacotherapy, Formulary, U.S.Pharmacistmore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close